Zosano Pharma (ZSAN) News Today → On June 10, Nvidia makes its next big move (From Weiss Ratings) (Ad) Free ZSAN Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share HeadlinesStock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative April 12, 2024 | seekingalpha.comHOOK HOOKIPA Pharma Inc.May 18, 2023 | bizjournals.comEast Bay Business NewsApril 6, 2023 | forbes.comAstellas PharmaFebruary 5, 2023 | finance.yahoo.comGiiant Pharma Receives Financial Support From the US Crohn’s and Colitis FoundationNovember 5, 2022 | ca.finance.yahoo.comZosano Pharma Corporation (ZSANQ)October 12, 2022 | msn.comBankrupt Zosano Sells Its Drug Delivery Tech That Once Partnered With Pharma GiantsAugust 28, 2022 | marketwatch.comBankrupt Zosano Pharma Says Unsecured Creditors Will Recoup 28% of ClaimsAugust 27, 2022 | bizjournals.comEast Bay migraine patch developer Zosano closes sale in bankruptcy court for $1 millionAugust 25, 2022 | investing.comZosano Pharma Corp (ZSANQ)July 26, 2022 | bizjournals.comEast Bay company promised drug-coated microneedle patches. Now it could be sold in bankruptcy court for just $1MJuly 26, 2022 | bizjournals.comA Fremont company promised drug-coated microneedle patches. Now it could be sold in bankruptcy court for just $1M.June 2, 2022 | marketwatch.comZosano Pharma Shares Slide to New Depths After Chapter 11 Filing >ZSANJune 2, 2022 | msn.comWhy Zosano Pharma Shares Are Getting Hammered TodayJune 2, 2022 | seekingalpha.comZosano Pharma files for Chapter 11 bankruptcy protection; shares plummet 46%June 2, 2022 | marketwatch.comCash-Strapped Zosano Pharma Files for Chapter 11 Bankruptcy >ZSANJune 2, 2022 | bizjournals.comEast Bay migraine patch developer files for bankruptcyJune 2, 2022 | finance.yahoo.comZosano Pharma Files Voluntary Petition for Relief Under Chapter 11June 2, 2022 | marketbeat.comTrading was temporarily halted for "ZSAN" at 07:06 AM with a stated reason of "News pending."May 18, 2022 | apnews.comEmergex Vaccines Announces the Successful Coating of its Novel CD8+ T cell Adaptive COVID-19 Vaccine onto Zosano Pharma’s Micro-Needle PatchMay 13, 2022 | investing.comZosano Pharma Reports Q1 Net Loss of $33.4MMay 13, 2022 | finance.yahoo.comZosano Pharma Reports First Quarter 2022 Financial ResultsMay 3, 2022 | finance.yahoo.comZosano Pharma Corporation (ZSAN) Outpaces Stock Market Gains: What You Should KnowApril 29, 2022 | bizjournals.comMigraine patch Zosano Pharma developer suspends program, cutting more jobsApril 29, 2022 | finance.yahoo.comMigraine patch developer Zosano Pharma suspends program, cutting more jobsApril 29, 2022 | seekingalpha.comZosano Pharma suspends program for migraine treatment M207April 29, 2022 | finance.yahoo.comZosano Pharma Provides Corporate UpdateApril 12, 2022 | seekingalpha.comZosano Pharma slips as reverse stock split takes effectApril 11, 2022 | finance.yahoo.comZosano Pharma Announces Reverse Stock Split Effective TodayMarch 26, 2022 | marketbeat.comZosano Pharma (NASDAQ:ZSAN) Receives New Coverage from Analysts at StockNews.comStockNews.com initiated coverage on shares of Zosano Pharma in a report on Saturday. They set a "sell" rating for the company.March 18, 2022 | benzinga.comLooking Into Zosano Pharma's Return On Capital EmployedMarch 18, 2022 | marketbeat.comZosano Pharma (NASDAQ:ZSAN) Coverage Initiated at StockNews.comStockNews.com initiated coverage on Zosano Pharma in a report on Friday. They issued a "sell" rating for the company.March 17, 2022 | finance.yahoo.comZosano Pharma Reports Fourth Quarter and Fiscal Year 2021 Financial ResultsFebruary 23, 2022 | marketbeat.comZosano Pharma (NASDAQ:ZSAN) Downgraded by BTIG ResearchBTIG Research cut Zosano Pharma from a "buy" rating to a "neutral" rating in a research note on Wednesday.February 9, 2022 | seekingalpha.comZosano Pharma plunges 48% on pricing $15.4M common stock and warrants offeringJanuary 5, 2022 | finance.yahoo.comZosano Pharma Announces Publication Of Early Data On Influenza VaccineJanuary 5, 2022 | finance.yahoo.comZosano Pharma Announces Publication of Clinical Data Demonstrating Comparable Immunogenicity of a Trivalent Influenza Vaccine Formulated on its Transdermal Microneedle System Versus an Intramuscular Injection of the Vaccine at a Higher DoseNovember 17, 2021 | finance.yahoo.comAiming to make Covid vaccines easier to take, East Bay company pushes forward with microneedle patchNovember 17, 2021 | finance.yahoo.comZosano Pharma Announces the Successful Formulation of a COVID-19 Vaccine Candidate on its Microneedle Patch SystemNovember 10, 2021 | finance.yahoo.comZosano Pharma Reports Third Quarter 2021 Financial ResultsNovember 1, 2021 | benzinga.comThinking about buying stock in Zosano Pharma, SoFi Technologies, Quantumscape, Nokia, or Hexo?October 26, 2021 | businesswire.comCSols Inc. Validates New LIMS at Zosano PharmaOctober 8, 2021 | benzinga.comZosano Pharma 8-K Shows Co. Refined Strategy For Resubmission Of M207 Microneedle System New Drug Application To FDAOctober 4, 2021 | finance.yahoo.comZosano Pharma Granted Type C Meeting with FDA Regarding NDA Resubmission for M207 Following Preliminary Top-Line Pharmacokinetic Study ResultsJuly 23, 2021 | seekingalpha.comZosano Pharma granted patent related to migraine treatment M207 Get Zosano Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ZSAN and its competitors with MarketBeat's FREE daily newsletter. Email Address The only financial event in 2024 that matters (Ad)Man Who Predicted 2008 Crash Warns of Black Swan Financial Event in 2024 Porter Stansberry’s new documentary is going viral. Stream the documentary for free by clicking here ZSAN Media Mentions By Week ZSAN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ZSAN News Sentiment▼0.000.78▲Average Medical News Sentiment ZSAN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ZSAN Articles This Week▼00▲ZSAN Articles Average Week Get Zosano Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ZSAN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: KLDO News Today GRFS News Today PROC News Today QLI News Today EVLO News Today STAB News Today AMPE News Today ATHX News Today ADTX News Today SXTC News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ZSAN) was last updated on 6/1/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProDems have chosen Biden replacement?Paradigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceNvidia is about to pass AppleWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zosano Pharma Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
